Research & Development

Eisai's Research & Development Activities for the Improvement of Access to Medicines (Product Creation)

September 12, 2018

At the Eisai Group, research and development (R&D) activities, which are the fundamentals of the subsequent downstream value chains through to the patients, are defined as “Product Creation”. For us, our R&D objective is not to simply carry out research and development, but rather it must be to provide patients with final drug products beneficial for them as a result of our efforts. By terming such activities as “Product Creation,” we are always reminded of our objective and our commitment to increasing patient benefits. Based upon ourhhcphilosophy, we are trying to understand the realities faced by patients and aiming to improve their quality of life by providing innovative medicines to satisfy both of their explicit and implicit healthcare needs. We believe that this is the objective of our Product Creation activities.

According to the concept of Product Creation, “Access to Medicines” (ATM) should be improved and secured for all patients. For example, proactive efforts toward developing medicines that address clear needs in developing countries, such as treatments for NTDs and three major infectious diseases (Malaria, TB and HIV/AIDS), are required to improve ATM, even though pharmaceutical companies in developed countries have not focused on those diseases so far. Eisai is working on various activities in order to deliver its medicines to more patients and people at risk around the world including developing countries without delay.

Regarding NTDs, Product Creation requires resources such as tools and technologies in order to do research into those diseases, experience with clinical trials in disease endemic regions and networks to clinical sites. Eisai has been establishing many partnerships for research projects, also known as Product Development Partnerships. These are formed as collaborative partnerships with international non-profit organizations that carry out specialized research on NTDs, are highly skilled at conducting clinical trials in disease endemic regions and have established global research networks. These partnerships maximize the strengths of each partner, and by utilizing public-private funding and external funds who support global health, allow for research and development to progress while sharing development risks and funding.

As of August 2018

NTDs/Three Major Infectious Diseases Research Project Portfolio

  • *
    Please click each item for details.
E1224 - Chagas Disease project (phase II study) Chagas vaccine (using Eisai's immunostimulant E6020) Novel compounds for Chagas Disease Chagas vaccine (using Eisai's immunostimulant E6020) Screening of novel compounds AWZ1066S E1224 - Eumycetoma project (phase II study) SJ733 (Phase I study) BRD5018 TLR9 antagonist for cerebral Malaria Novel compound for artemisinin resistant malaria Inhibitor of Plasmodium GWT1 Screening of novel compounds for malaria Malaria vaccine (using Eisai's immunostimulant E6020) Screening of novel compounds
WIPO Re:Search NTD Drug Discovery Booster Macrofilaricide Drug Accelerator TB Drug Accelerator
Disease
Chagas Disease
Project Name
E1224 - Chagas Disease project (phase II study)
Partner
DNDi
E1224 (fosravuconazole) is an antifungal compound discovered by Eisai which was found to exhibit potent activity against Chagas disease by Dr. Urbina in Venezuela. Based on this finding, in September 2009, Eisai and the Drugs for Neglected Disease initiative (Headquarters: Geneva, Switzerland, “DNDi”), an independent non-profit organization, entered into a collaboration and license agreement for the clinical development of E1224, and currently the two organizations are jointly conducting a Phase II Clinical Study of E1224 as a treatment for Chagas disease in South America.
Related URL
Disease
Chagas Disease
Project Name
Chagas vaccine (using Eisai's immunostimulant E6020)
Partner
Sabin Vaccine Institute
In August 2014, Eisai entered into a joint research agreement with the Sabin Vaccine Institute (Washington D.C., United States, “Sabin”), the Baylor College of Medicine (Houston, Texas, United States) and Aeras (Rockville, Maryland, United States) to develop a vaccine for Chagas disease. This research was jointly initiated by Eisai and Sabin in 2012 with the aim of developing a new vaccine that utilizes Eisai's in-house discovered selective TLR4 agonist, E6020, as a novel adjuvant (a substance that enhances immune effects). If development of this novel anti-Chagas disease vaccine succeeds, it could potentially prevent cardiac complications from Chagas disease and slow onset of the disease.
Related URL
Disease
Chagas Disease
Project Name
Novel compounds for Chagas Disease
Partner
Broad Institute
In November 2013, Eisai and the Broad Institute (Cambridge, Massachusetts, United States, “Broad”) entered into an agreement to jointly discover and develop new therapeutic agents for the treatment of neglected tropical diseases (NTDs) and tuberculosis. Under the agreement, Eisai and Broad will collaborate together on optimization of compounds screened from Broad's unique chemical library. The first project will conduct drug discovery research aimed at the creation of a novel treatment for Chagas disease, an NTD.
Related URL
Disease
Chagas Disease
Project Name
Chagas vaccine (using Eisai's immunostimulant E6020)
Partner
Fiocruz
Aiming to develop vaccines or treatments that target malaria and other neglected tropical diseases (NTDs), Eisai agreed to work together comprehensively on joint research with Fundação Oswaldo Cruz (Rio De Janeiro, Brazil, “Fiocruz”) in October 2012. Under this agreement, fundamental research will be conducted for the development of a vaccine for Chagas disease. Eisai will provide its in-house discovered selective TLR4 agonist, E6020, for use as a vaccine adjuvant (a substance that enhances immune effects).
Related URL
Disease
Chagas Disease
Leishmaniasis
Project Name
Screening of novel compounds
Partner
DNDi
As exploratory research into novel compounds for Chagas disease and Leishmaniasis, Eisai is collaborating with Drugs for Neglected Diseases initiative (Headquarters: Geneva, Switzerland, “DNDi”) on screening new drug candidates from the compound library provided by Eisai.
Related URL
Disease
Filariasis
Project Name
AWZ1066S
Partner
Liverpool School of Tropical Medicine
University of Liverpool
In March 2014, Eisai commenced research in collaboration with the Liverpool School of Tropical Medicine (Liverpool, United Kingdom) and the University of Liverpool (Liverpool, United Kingdom) to jointly identify new drugs effective against lymphatic filariasis and onchocerciasis (river blindness), both major types of filariasis. The goal is to develop a treatment that can effectively eradicate the worms that cause filariasis by first eliminating the Wolbachia bacteria inside them which the worms (filariae) depend upon for growth, development and survival. AWZ1066S has been identified as a candidate drug for advancing clinical studies.
Related URL
Disease
Mycetoma
Project Name
E1224 - Eumycetoma project (phase II study)
Partner
DNDi
In September 2015, The Drugs for Neglected Diseases initiative (Headquarters: Geneva, Switzerland, “DNDi”) and Eisai signed an agreement to proceed with clinical development of Eisai's anti-fungal drug E1224 (fosravuconazole) for the treatment of eumycetoma, a fungal form of mycetoma, one of the world's most neglected diseases. E1224 is being investigated in a clinical trial started in 2017 in collaboration with the Mycetoma Research Center (MRC) of the University of Khartoum, Sudan.
Related URL
Disease
Malaria
Project Name
SJ733 (Phase I study)
Partner
University of Kentucky 
MMV
Eisai entered into a joint research agreement with University of Kentucky (Lexington, Kentucky, the United States) and Medicines for Malaria Venture (Headquarters: Geneva, Switzerland, “MMV”) to develop a new antimalarial medicine. This partnership aims to develop a new medicine that will be rapidly effective, cure in a single dose and provide lasting protection against reinfection. A Phase I clinical study was initiated in March 2016. If development succeeds, the treatment could potentially solve the problem of increased resistance faced by current antimalarial medicines.
Related URL
Disease
Malaria
Project Name
BRD5018
Partner
Broad Institute
MMV
In September 2014, Eisai entered into a joint research agreement with the Broad Institute (Cambridge, Massachusetts, United States, “Broad”) to develop a new antimalarial treatment. Eisai and Broad work together to jointly evaluate compounds screened from Broad's library and identified BRD5018, a compound with the potential to be used in clinical trials. The goal of this research is to develop an oral medicine that will rapidly cure malaria, and by interrupting the transmission of plasmodium (the parasite that causes malaria), will prevent malaria reinfection.
Related URL
Disease
Malaria
Project Name
TLR9 antagonist for cerebral Malaria
Partner
Fiocruz
Aiming to develop vaccines or treatments that target malaria and other neglected tropical diseases (NTDs), Eisai agreed to work together comprehensively on joint research with Fundação Oswaldo Cruz (Rio De Janeiro, Brazil, “Fiocruz”) in October 2012. The first project of this partnership is to conduct joint research on the active TLR9 antagonist, E6446, discovered by Eisai and similar compounds as a potential treatment for cerebral malaria.
Related URL
Disease
Malaria
Project Name
Novel compound for artemisinin resistant malaria
Partner
Liverpool School of Tropical Medicine
University of Liverpool
In November 2015, Eisai joined a research program with the Liverpool School of Tropical Medicine (Liverpool, United Kingdom) and the University of Liverpool (Liverpool, United Kingdom) to conduct preclinical development of a new antimalarial candidate compound E209. E209 is expected to be effective in patients for whom artemisinin-based malaria treatments are ineffective due to resistance.
Related URL
Disease
Malaria
Project Name
Inhibitor of Plasmodium GWT1
Partner
MMV
Eisai has identified GWT1 as a novel drug target of malaria parasites, and furthermore, has identified in-house compounds that inhibit the function of GWT1. Exploratory research starting from these identified compounds in collaboration with Medicines for Malaria Venture (Headquarters: Geneva, Switzerland, “MMV”) is in progress, and is currently at the compound optimization stage.
Related URL
Disease
Malaria
Project Name
Screening of novel compounds for malaria
Partner
MMV
Eisai established a new collaboration with the Medicines for Malaria Venture (Headquarters: Geneva, Switzerland, “MMV”), a non-profit organization, to conduct screening of Eisai's proprietary compound library in malaria specific assays.
Related URL
Disease
Malaria
Project Name
Malaria vaccine (using Eisai's immunostimulant E6020)
Partner
Fiocruz
Aiming to develop vaccines or treatments that target malaria and other neglected tropical diseases (NTDs), Eisai agreed to work together comprehensively on joint research with Fundação Oswaldo Cruz (Rio De Janeiro, Brazil, “Fiocruz”) in October 2012. Under this agreement, fundamental research will be conducted for the development of a vaccine for malaria. Eisai will provide its in-house discovered selective TLR4 agonist, E6020, for use as a vaccine adjuvant (a substance that enhances immune effects).
Related URL
Disease
Tuberculosis
Project Name
Screening of novel compounds
Partner
Broad Institute
Colorado State University
The University of Chicago
The Broad Institute (Cambridge, Massachusetts, United States, “Broad”) and Eisai entered into a joint research agreement for the development of a novel anti-tuberculosis (TB) treatment in March 2018. Novel azetidine compounds that demonstrate anti-TB activity discovered so far by Broad are being jointly evaluated, and an optimal candidate drug will be identified for advancing clinical studies. This research aims to find a small molecule compound that possesses favorable physicochemical properties and pharmacokinetics, potent anti-TB activity that inhibits tryptophan synthase in Mycobacterium sp., and exhibits positive safety and efficacy.
Related URL
Consortium Project Name
WIPO Re:Search
Partner
WIPO
BVGH
Eisai is a member of the World Intellectual Property Organization (WIPO) Re:Search Consortium, an international joint enterprise for the development of treatments for NTDs led by WIPO. Based on requests from academic researchers worldwide involved in research into NTD treatments, Eisai is providing various biologically active compounds free of charge through this consortium. The intellectual property rights associated with these compounds are basically provided royalty free for use in development of NTD treatments and commercialization in countries where target NTDs are endemic.

Related URL

Consortium Project Name
NTD Drug Discovery Booster
Partner
DNDi
The “Neglected Tropical Diseases Drug Discovery Booster” consortium was formed in May 2015 with the aim of accelerating early stage drug discovery for Leishmaniasis and Chagas disease, through a multilateral, coordinated search process across screening systems and compound libraries owned by participating companies under the leadership of the Drugs for Neglected Diseases initiative (DNDi). Eisai joined the consortium as one of four founding companies (Eisai Co. Ltd., Shionogi & Co. Ltd., Takeda Pharmaceutical Ltd., and AstraZeneca plc). Currently, more companies have joined the consortium. This innovative research model has the potential to cut up to two years from the early drug discovery process, which generally takes approximately five years or more.
Related URL
Consortium Project Name
Macrofilaricide Drug Accelerator
Partner
Bill & Melinda Gates Foundation
Eisai has joined the Macrofilaricide Drug Accelerator (MacDA) in March 2015. This program is a collaborative drug discovery partnership led by the Bill & Melinda Gates Foundation which includes four academic institutions, five pharmaceutical companies, and two non-profit institutions uniting to support the discovery of macrofilaricide agents.
Current available drugs for the treatment of filarial infections (such as lymphatic filariasis and onchocerciasis) are effective against the young forms of the worms (microfilaricidal drugs, such as diethylcarbamazine, albendazole, ivermectin). In order to achieve elimination of these diseases, there is an urgent need for medicines effective against the adult forms of the worms.
The primary goal of the MacDA is to accelerate the discovery of lead macrofilaricide drug compounds (defined as agents that kill or permanently sterilize adult filarial worms) that can be developed into new therapies for filariasis, especially onchocerciasis, through the development and use of innovative technologies. The MacDA Members intend to work in collaboration, united by a robust system for the exchange of data and materials, supported by the Bill & Melinda Gates Foundation.
Consortium Project Name
TB Drug Accelerator
Partner
Bill & Melinda Gates Foundation
In November 2013, Eisai became a signatory to the Tuberculosis Drug Accelerator (TBDA) partnership, a groundbreaking initiative that aims to speed up the discovery of essential new treatments for tuberculosis (TB). Jointly launched in June 2012 through a collaborative agreement among seven pharmaceutical companies and six research institutions with support from the Bill & Melinda Gates Foundation, this partnership targets the discovery of new TB drugs by working together on early-stage research. Accordingly, Eisai and all other participating companies will provide their compound libraries for screening anti-TB drugs, and by sharing candidate compounds with the other partners when they are identified, will cooperate in order to rapidly and efficiently create a new therapy for TB.
Related URL